October 15, 2024 10:41 GMT
HEALTHCARE: Johnson & Johnson (JNJ: Aaa/AAA neg): R&D Expense
HEALTHCARE
- Worth highlighting the increase of R&D from 16.2% of sales to 22%.
- A 43.7% increase yoy as the company tries to replace its Pharma (Innovative Medicine) pipeline
- This was a $1.5bn extra cost which went some way to explaining the drop in Net Earnings
42 words